Category: Clinical Trials
Trial design, phases, endpoints, results, status changes and interpretation of registered clinical research.
Weight Regain After Stopping GLP-1 Medicines: What Trials Show
Compare STEP 1, STEP 4 and SURMOUNT-4 withdrawal findings, their study timelines and weight-change denominators, and limits on predicting individual regain.
Read analysis →Semaglutide and Kidney Disease: What the FLOW Trial Shows
FLOW tested semaglutide in 3,533 adults with type 2 diabetes and chronic kidney disease. Read the kidney outcomes, evidence limits and Australian TGA status.
Read analysis →CagriSema Trial Results: What REDEFINE 1 and REDEFINE 2 Actually Show
CagriSema combines cagrilintide and semaglutide. Read the phase 3 REDEFINE 1 and 2 results, analysis methods, safety findings and evidence limits.
Read analysis →MASH and MASLD Drug Evidence: FDA Decisions and Trial Tracker
Track MASH drug evidence across FDA decisions and primary trials, with biopsy endpoints, analysis populations and confirmatory-outcome limits kept separate.
Read analysis →Oral GLP-1 Medicines: Approval and Clinical-Trial Evidence Tracker
Compare FDA decisions and primary trial evidence for oral semaglutide and orforglipron, with dates, trial identifiers and clear limits on comparisons.
Read analysis →Obesity Drug Clinical Trial Results Tracker (2026)
A continuously updated, source-linked tracker of major 2026 obesity-drug trial results, including retatrutide, CagriSema, survodutide and petrelintide.
Read analysis →How to Read a Weight-Loss Drug Trial: Endpoints, Dropouts, Safety and Comparisons
An evidence-literacy guide to weight-loss drug trials: populations, endpoints, estimands, missing data, discontinuations, safety and cross-trial comparisons.
Read analysis →CJC-1295 and Ipamorelin: Evidence, FDA Safety Flags and 2026 WADA Status
CJC-1295 and ipamorelin are often marketed together, but they are different growth-hormone-pathway substances with limited clinical evidence and distinct safety questions.
Read analysis →Press Release vs Peer-Reviewed Paper: A Six-Question Evidence Check
How to interpret topline trial announcements before the full protocol, tables and peer-reviewed paper are available.
Read analysis →CagriSema REIMAGINE 2: What the Published Phase 3 Trial Shows
REIMAGINE 2 published results: HbA1c, safety and trial limits, with sponsor headlines compared against the peer-reviewed phase 3 paper.
Read analysis →